Cannabis Stock News- Investing in Cannabis and Hemp Stocks

Friday, July 24, 2020

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 446 (TSX: $AVCN.TO) (TSX: $HEXO.TO) (TSX: $ZENA.TO) (OTC: $EHVVF)

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 446 (TSX: $AVCN.TO) (TSX: $HEXO.TO) (TSX: $ZENA.TO) (OTC: $EHVVF)

Delta, Kelowna, BC, July 24, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2020/072420-StocksToWatch.mp3

Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/07241AVCN-HEXO-ZENA-EHVVF.asp

Hear the investor ideas potcast on Spotify

Hear Investor ideas cannabis potcast on iTunes

Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today’s podcast we look at a few public company announcements.

Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announced that the Company's research collaborators have received two independent peer-reviewed grants from the Natural Sciences and Engineering Research Council of Canada. The NSERC Alliance grants will be used to expand the investigators' collaborative research with Avicanna.

For the past three years, Dr. Christine Allen's research group (CARG) in the Leslie Dan Faculty of Pharmacy at the University of Toronto has supported the development and optimization of Avicanna's cannabinoid-based products including commercial cosmetics (Pura H&W) and medical cannabis (Rho Phyto) product lines and the pharmaceutical pipeline that is currently under clinical investigation. Dr. Allen will now leverage a recent MITACS award in addition to this NSERC Alliance grant in collaboration with Avicanna to develop a cannabinoid-based formulation for treatment of COVID-19 related lung inflammation.

A second NSERC Alliance grant was awarded to Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, who has an extensive track-record in behavioural pharmacology and neuroscience. Avicanna's research program with Dr. Khokhar focuses on evaluating a variety of cannabinoids in several preclinical models of human psychiatric conditions including mental health disorders such as anxiety, depression, and PTSD. The NSERC grant was awarded to evaluate the neurobiological underpinnings of cannabis toxicosis in a preclinical model, and test the potential efficacy of Avicanna's naturally-derived cannabinoids and formulations in the treatment of cannabis-induced toxicosis. With the recent changes in the Canadian regulations for Cannabis 2.0 allowing for cannabinoid edibles and vapes, there is concern around an increased risk for adverse events arising from accidental high-dose cannabis ingestion. Thus, this two-year project will determine the behavioural and neural correlations of cannabis-induced toxicosis and the effects of cannabinoids for counteracting cannabis-induced toxicosis.

Dr Jibran Khokhar, commented, "This research is extremely timely with the new Cannabis 2.0 regulations and the increased risk for cannabis-induced toxicosis. I am thankful to NSERC and Avicanna for support of this important research that will have an impact in our understanding of the neurobiological underpinnings of, and provide novel treatment avenues to treat, adverse events related to high-dose cannabis exposures."

HEXO Corp (TSX: HEXO) (NYSE: HEXO) announced the launch of its line of vape products to both adult-use and medical consumers, across Canada.

“At HEXO, we pride ourselves in ensuring our consumers have access to high-quality, reliable and consistent cannabis products,” said Sebastien St. Louis, CEO and co-founder of HEXO Corp. “We are thrilled to launch our vape products across Canada as we continue to focus on innovation and launching additional 2.0 products across all of our brands.”

Prior to releasing its line of vapes, the Company conducted testing to evaluate the taste, tolerability of effects and short-term undesired effects of its proprietary terpene blends.

HEXO’s vape products currently include three ready-to-use vape pens and four 510-thread cartridges, in popular strain-inspired terpene blends. HEXO vapes are available across Canada to both adult-use and medical consumers.

Zenabis Global Inc. (TSX: ZENA) today announced initial shipments of its Re-Up 510-Threaded Vaporizer line.

This week, Zenabis completed first shipments of this new product line, which is produced at Zenabis Atholville using product cultivated and extracted by Zenabis, with no requirement for third-party processing. Currently, the product offering includes two high THC products and one CBD product. Zenabis currently has listings of this product in five provinces and anticipates listings in an additional three provinces by the end of August.

Zenabis anticipates that its 510-Threaded Vaporizer line will contribute meaningfully to net revenue from August 2020 onward given consumer preference for the Re-Up 510-Threaded Vaporizer line of products. Thus far, all offers made under the Re-Up 510 Threaded Vaporizer line have been accepted by provincial counterparties. Zenabis has focused on achieving differentiation in this product line through:

● A focus on competitive, best-in-class pricing (targeting lowest retail pricing versus competitors in all available provincial markets); and

● Products based on terpene flavour profile, as opposed to cultivar.

Zenabis created this product line with a focus on consumer education and experience. The Re-Up 510-Threaded Vaporizer line of products was developed by our product development team to assist consumers in better understanding the botanical nature of terpenes. Each vaporizer cartridge type was developed with a purposefully curated selection of terpenes with complementary flavour profiles and similar characteristics. The initial launch of the

Re-Up 510-Threaded Vaporizer product line will include two high THC vaporizer cartridges: (i) Lemon and Lavender; and (ii) Hops and Spice, as well as one high CBD vaporizer cartridge, Pine and Berry. The Re-Up 510-Threaded Vaporizers product line will be available in two formats, 0.5g and 1.0g, and fit all standard 510 thread vaporizer pens.

Kevin Coft, Chief Executive Officer of Zenabis, stated, "We are very excited to have completed initial shipments under this product line, especially given that this was achieved through full, internalized production of these products at Zenabis Atholville utilizing in-house extraction and filling. We believe that the Re-Up 510-Threaded Vaporizer line is a strong complement to our existing, premium Pax Era line of vaporizer cartridges." Olen Vanderleeden, Senior Vice President of Zenabis added, "Based on indications from provincial counterparties and considering our competitive pricing, Zenabis anticipates incremental monthly revenue in excess of one million dollars per month once production at Zenabis Atholville rises to a level to meet consumer demand."

Ehave, Inc. (OTC : EHVVF) and its subsidiary PsyTech announced today an upcoming Psychedelic Industry webinar for investors and interested individuals. PsyTech was incubated by iCAN (Israel-cannabis) and developed by the team behind CannaTech, the premier international cannabis summit. Leveraging the highly relevant experience of iCAN, PsyTech is positioned to lead the global psychedelic conversation forward.

Ehave CEO Ben Kaplan said, "Our PsyTech Conferences have been very popular with investors, as a result of their insight on the industry. Psychedelic medicine has garnered a tremendous amount of attentions since The U.S. Food and Drug Administration (FDA) authorized Breakthrough Therapy Designation to both Compass Pathways' and Usona Institute's psilocybin therapy for depression in 2018." Mr. Kaplan continued, "The mainstream media started talking about it late last year after a group of private donors donated $17 million to start the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine. We expect our complimentary webinar on July 29 will continue our trend of providing important information on psychedelic medicine to investors.''

The virtual investor webinar titled Mystical Experience, Religion, and Psychedelics is open to individual investors, institutional investors, advisors, analysts and the Psychedelic Community. The program opens at 12:00 PM ET on Wednesday, July 29^th.

Speakers for the PsyTech Virtual Investor Conference include:

Irie Selkirk - Moderator

Director of Rise Wellness Retreat and Co-Founder of Sansero Life Sciences

Pastor James Lindberg

An Ordained Clergy Person at The Evangelical Lutheran Church in America

Rabbi Zac Kamenetz

Founder and CEO of Shefa: Psychedelic Therapy Grounded in Jewish Spirituality

William A. Richards

Psychologist - The Center for Psychedelic And Consciousness Research At The Johns Hopkins University School Of Medicine

There are no fees to log-in, or attend the live presentations.

Please support our partner organization, Mind Medicine Australia, by registering for their upcoming summit on psychedelic therapies for mental illness. MMA is offering a special 10% discount code to the PsyTech community. Just use the code ‘MMA2020’ on their website when purchasing an event package.

https://summit.mindmedicineaustralia.org

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

Hear Investor ideas cannabis potcast on iTunes

Hear the investor ideas potcast on Spotify

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info:

https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:

https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

Thursday, July 23, 2020

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 445 (CSE: $CURA.C) (TSXV: $KHRN.V) (TSX: $FAF.TO) (TSX: $LABS.TO) (OTCQB: $TECR)

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 445 (CSE: $CURA.C) (TSXV: $KHRN.V) (TSX: $FAF.TO) (TSX: $LABS.TO) (OTCQB: $TECR)

Delta, Kelowna, BC, July 23, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2020/072320-StocksToWatch.mp3

Read this in full at http://www.investorideas.com/news/2020/cannabis-potcasts/07231CURA-KHRN-FAF-LABS-TECR.asp

Hear Investor ideas cannabis potcast on iTunes

Hear the investor ideas potcast on Spotify

Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today’s podcast we look at a few public and private company announcements.

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF), the largest vertically integrated cannabis operator in the United States, today announced that it closed its milestone acquisition of GR Companies, Inc., the largest private vertically-integrated multi-state operator in the United States, on July 23, 2020.

With completion of the acquisition of Grassroots, Curaleaf is the world's largest cannabis company by revenue and the most diversified vertically integrated cannabis company in the United States, the world's largest cannabis market. The transaction expands Curaleaf's presence from 18 to 23 states, with the combined company having affiliated operations spanning over 135 dispensary licenses, 88 operational dispensary locations, over 30 processing facilities and 22 cultivation sites with 1.6 million square feet of current cultivation capacity. Curaleaf's expanded geographic dispensary presence now offers access to medical or adult use Cannabis to more than 192 million people, or roughly two-thirds of the United States population.

"The successful acquisition of Grassroots marks Curaleaf's expansion into new vertically integrated markets in the Midwest, firmly establishing our U.S. market leadership position. This highly complementary combination brings together two companies with a shared vision for enhancing patients' and customers' lives with high-quality cannabis wellness and lifestyle products. I'd like to welcome all our new Grassroots colleagues, patients and customers to the Curaleaf family as we pursue our mission of improving lives by providing clarity around cannabis and confidence around consumption," commented Joseph Lusardi, CEO of Curaleaf. "The integration of Grassroots is expected to be immediately accretive to our financial performance, with our unprecedented scale providing significant opportunities to leverage Curaleaf's powerful consumer brands as well as new form factor innovations across our expanded national presence."

Completion of the transaction strategically accelerates Curaleaf's expansion into Illinois and Pennsylvania, which are among the largest and fastest-growing cannabis markets in the United States. Upon close, Curaleaf will hold a leading licensed cannabis presence in state markets including Arizona, Connecticut, Florida, Illinois, Pennsylvania, Maryland, Massachusetts, Maine, Nevada, New Jersey, New York, North Dakota, and Vermont.

The cultivation and processing assets in Illinois have been transferred and the formal approval to transfer certain retail assets is expected imminently. Maryland operations previously affiliated with Grassroots may be transferred to Curaleaf after expiration of the statutory hold period, subject to regulatory approval and compliance with restrictions on ownership or control of multiple cultivation, processor and dispensary licenses in the State.

Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF), a vertically integrated cannabis leader with core operations in Latin America and Europe, announced today that it has received import licenses and all necessary authorizations from the Directorate General of Drug Supplies and Drugs (DIGEMID) for the import and commercialization of full spectrum, high-CBD medical cannabis products from Khiron Colombia into Peru.

"Successfully completing all licensing, import and distribution requirements allows us to bring our full spectrum, high CBD medical cannabis products into Peru. We have an experienced country management team in place in Lima and, together with our distribution partner Farmacia Universal, are now positioned to give patients in Peru greater access to medical cannabis therapies. Additionally, we anticipate fulfilling all necessary requirements to commercialize high-THC medical cannabis products in Peru during Q4 2020," comments Luis Marquez, Khiron Peru Country Manager.

In Peru, only registered pharmaceutical establishments that have received Good Storage Practices (GSP) certification are authorized to participate in the wholesale import and commercialization of cannabis products. Khiron Peru is a GSP certified, registered pharmaceutical establishment, and Farmacia Universal has all required permits, including Good Manufacturing Practices (GMP) certification, to distribute medical cannabis final products to patients through pharmacies under the previously announced agreement with Khiron.

With receipt of the final licenses and authorizations from DIGEMID, Khiron Peru is now fully authorized to import full spectrum, high-CBD medical cannabis from Khiron Colombia, which is now fully authorized by the Narcotics National Fund (NNF) in Colombia for the export to Peru. The Company anticipates prescriptions can be filled commencing in Q3 2020.

"Entry to the Peru medical cannabis market continues our relentless focus on meeting patient needs in Latin America and globally. We are currently the only company in Colombia that has dispensed medical cannabis to patients and have now surpassed our first 1,000 medical cannabis patient prescriptions milestone. This, despite a global pandemic that has slowed down many of the world's economies, represents a very important achievement for us," comments Alvaro Torres, Khiron CEO and director.

Fire & Flower Holdings Corp. and its wholly-owned subsidiary Fire & Flower Inc. (TSX: FAF) (OTCQX: FFLWF), today announced that it has received the Approval in Principle from the Liquor and Cannabis Regulation Branch of the province of British Columbia for two cannabis retail stores located in Vancouver, British Columbia.

Receiving the AIP is one of the final steps required for licensing cannabis retail stores in the province of British Columbia, and the receipt of the AIPs presents a clearer path for the Company's entry into this new market.

The AIPs come upon the LCRB completing its eligibility and suitability assessment of Fire & Flower and the Company was found to be "fit and proper" for the purposes of receiving final licenses upon satisfactory inspection of the finished stores in accordance with the AIPs.

"Fire & Flower is very pleased to be entering the province of British Columbia in the key urban market of Vancouver. We have been poised to launch stores in the province for some time as part of our national growth strategy," shared Trevor Fencott, Chief Executive Officer of Fire & Flower. "It is encouraging to see the province of British Columbia move forward with additional cannabis retail licenses. The issuance of additional licenses is a key step in the eradication of the illicit cannabis market and licensing in the province is an important step in the growth of the legal cannabis industry."

Once opened, the Vancouver Fire & Flower stores will be located at:

● 2231 Granville Street, Vancouver, British Columbia, and

● 2570 Granville Street, Vancouver, British Columbia.

Opening dates and times of the Vancouver Fire & Flower stores will be announced on the Company's website at www.fireandflower.com/locations/ and through social media at the earliest opportunity.

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) today announced its Australian operation – MediPharm Labs Australia Pty. Ltd. – has reached its first month operational milestone, with approximately $500,000 AUD, of formulated products delivered to customers in Australia, on its way to developing a strong commercial presence in international markets.

“MediPharm Labs Australia was conceived as a part of our strategy to develop a multi-jurisdictional, GMP-certified production capability for worldwide medicinal, wellness and adult-use markets and since opening at the end of 2019, it has signed a number of significant domestic and international customer supply agreements,” said Pat McCutcheon, Chief Executive Officer, MediPharm Labs. “To reach this revenue milestone this quickly – in fact just two months after receiving Australian GMP certification – is positive proof of the demand for our capabilities and formulations and that our international team is beginning to hit its stride. I congratulate my colleagues in Australia for what will be the first of many milestone accomplishments.”

The Company’s Australian facility was certified by the Therapeutic Goods Administration as meeting the GMP standard and secured a Licence to Manufacture Therapeutic Goods in May 2020. As the Company’s Canadian facility was TGA GMP certified in late 2019, MediPharm Labs has created a global pharmaceutical-quality supply chain that is qualified to serve new emerging medical markets internationally.

“Speaking on behalf of our local team, we couldn’t be more excited by this development and the long-term potential we have to lead our markets,” said Warren Everitt, CEO, Asia Pacific, MediPharm Labs. “Our first month of operations included shipments of approximately $500,000 AUD comprising formulated CBD and THC oils that our customers can trust for quality and reliability. These shipments are the product of synergies between our Canadian and Australian facilities as they were made possible by a large shipment of finished products and bulk oil from our sister GMP-certified facility in Barrie, Ontario. We intend to continue taking advantage of our internal supply pipeline on a strategic basis as we expand our international market share.”

On July 21, 2020, the board of directors of Citrine Global Corp. (OTCQB: TECR) approved for its wholly-owned Israeli subsidiary CTGL - Citrine Global Israel Ltd. to take part in a joint venture for the establishment of a “Cannovation Center” - Cannabis Innovation Center - in Israel to address the needs of the emerging cannabis, CBD and hemp industry. CTGL - Citrine Global Israel Ltd will hold around 60% of the Cannovation Center.

The Cannovation Center is a unique, all-in-one platform with factories for producing cannabis, hemp and CBD products, laboratories and a logistics and distribution center, for supporting the cannabis eco-system, including cannabis growers, cannabis product developers, researchers and businesses, that operate in a field that requires interdisciplinary professional expertise and compliance with a wide set of regulatory demands, including IMC-GMP production standards, 24/7 surveillance and security, special recycling procedures, and more.

The Cannovation Center in Israel will provide solutions for companies in Israel and worldwide, leveraging Israel’s leadership in cannabis innovation and promoting the production and distribution of cannabis, hemp and CBD products for local and global markets.

The Cannovation Center is in the process of obtaining a government grant. The Israeli Government provides grants and subsidies specific to the cannabis industry as part of its strategy for boosting the economy through technological innovation.

Ora Meir Soffer, Citrine Global's Chairperson and CEO, stated: "Israel is a leading source of technological innovation, including in the cannabis industry. Our Cannovation Center venture is a result of years of involvement in the cannabis industry, and we are confident that the Cannovation Center will provide a solution for the needs of the cannabis industry. We are happy that CTGL - Citrine Global Israel Ltd will be a part of this. We hope this will be the first center, to be joined by additional centers around the world".

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

Hear Investor ideas cannabis potcast on iTunes

Hear the investor ideas potcast on Spotify

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:

https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

Wednesday, July 22, 2020

Investorideas.com - Cannabis Deal Tracker: Investment and M&Amp;Amp;A Activity in the Cannabis Industry July 13th - July 17th, 2020

Tuesday, July 21, 2020

Investorideas.com - Psychedelic Stock News: Nutritional High (CSE: EAT) Announces Closing of Psychedelic Science Corp's Private Placement of Units

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 444 (CSE: $DOSE.C) (OTC: $MJNA) (OTCQB: $AXIM)(CSE: $XCX.C)

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 444 (CSE: $DOSE.C) (OTC: $MJNA) (OTCQB: $AXIM)(CSE: $XCX.C)

Delta, Kelowna, BC, July 21, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2020/072120-StocksToWatch.mp3

Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/07211DOSE-MJNA-AXIM-XCX.asp

Hear the investor ideas potcast on Spotify

Hear Investor ideas cannabis potcast on Apple iTunes

Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today’s podcast we look at a few public and private company announcements.

Rapid Dose Therapeutics Corp. (CSE: DOSE), a Canadian Life Sciences company focused on innovative drug and active ingredient delivery solutions, announced that it has begun COVID-19 vaccine research in conjunction with McMaster University and the team lead by Drs. Alex Adronov, James Mahony, and Mark Larché. The federally-funded project tests the use of QuickStrip™ for administering vaccines orally as a convenient and safe alternative to injection with needles, the currently accepted delivery format for most vaccines.

Dr. Adronov is a recognized Canadian expert in synthetic polymer chemistry and the development of novel polymer architectures, Dr. Mahony has extensive experience in virology and vaccine development, and Dr. Larché is an immunologist with expertise in vaccine research geared toward treatment of common allergies. The combined expertise of this research team will enable development and evaluation of oral vaccine delivery strategies.

Jason Lewis, RDT SVP said “RDT is focused on novel research through collaboration with the experts at McMaster. We see QuickStrip™, oral mucosa thin film delivery, as an efficient solution for distributing vaccines globally. Experts believe that antigens to COVID and other viruses can be delivered sublingually, a much easier and less expensive process than the current single or multidose vial methods. Imagine the significance of creating a vaccine that can be sent in an envelope, by mail.”

“Our combined experience indicates that this is very feasible” said Dr. Adronov a recognized polymer expert leading the research project. “Our past collaborations with RDT in developing polymeric delivery innovations have resulted in solutions we are proud of, and continue to be involved with. Globally, we are seeing the development of many vaccines that we believe can be applied using sublingual delivery. Our project focuses on producing a polymer strip that delivers viral antigens by a transmucosal approach rather than injection. This funding will allow us to quickly get started, and we expect to generate positive results in the near future.”

Mark Upsdell, RDT CEO, said “The current COVID situation requires everyone to think outside of the box as to how we might deliver safe, effective and timely solutions for combating COVID-19 and other viruses that require serum-based defenses. RDT remains committed to its research and innovation strategy which is highlighted now by our work on the COVID-19 project’s unique delivery format. RDT provides scale-up testing and bench strength support for the McMaster research team in the race to provide an effective product that can be produced and delivered on a world-wide scale. A successful outcome of this project and its application with our QuickStrip™ delivery system will create exciting new opportunities for RDT.”

Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its investment company AXIM® Biotechnologies, Inc. (OTCQB: AXIM) has announced the development of a rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 (COVID-19) from infection.

Medical Marijuana, Inc. CEO Dr. Stuart Titus commented: “Our portfolio is proud to see the innovation that AXIM has showcased over the past few months and we are optimistic that this test could help make a difference in achieving our end-goal of overcoming this virus. Personally, I think that this kind of ingenuity will set us apart from our competitors and allow us to continue to grow the other facets of our business.”

Unlike currently available COVID-19 tests that detect an antibody response to the virus, AXIM’s rapid 10-minute test measures a specific subpopulation of antibodies to block the virus from attacking a person’s body. While there are expensive, time-consuming laboratory tests that measure neutralizing antibodies, this test could be offered with easier convenience, lower cost and much faster -- results in 10 minutes -- than any other test on the market.

AXIM’s test could also help ensure that vaccines elicit high levels of neutralizing antibodies. When a vaccine is available, manufacturers can employ this test to evaluate its effectiveness in vaccine recipients.

“We have succeeded at creating a test that is cost-efficient, accurate and fast – hopefully serving as an ‘Immunity Passport™’ for vaccine developers as they begin larger Phase II and III clinical trials,” AXIM® Biotech CEO John W. Huemoeller II said.

AXIM has filed a Pre-Emergency Use Authorization and is compiling the necessary data from numerous tests recently completed that are needed to apply for an EUA from the FDA. AXIM makes clear that while the Company intends to file an EUA with the U.S. FDA, the U.S. FDA has not yet approved the Company’s diagnostic test and there is no guarantee that any EUA once filed will be approved.

AMP German Cannabis Group Inc. (CSE: XCX) announced that it has placed two orders for bulk and finished EU-GMP medical cannabis flower from a Canadian Licensed Producer of medical cannabis. AMP will be purchasing and importing to Germany, 50 kilograms of EU-GMP medical cannabis in September 2020 and a further 100 kilograms during January/February 2021. AMP and the Canadian LP plan to expand the supply agreement for monthly large volume purchases of medical cannabis as well as extracts.

The Canadian LP operates an indoor growing and processing facility in Canada and was already EU-GMP certified by German authorities earlier this year.

Dr. Stefan Feuerstein, President of AMP, commented, "We are seeing a stronger than anticipated demand for medical cannabis in the German marketplace and Canada is one of a few credible suppliers to Germany in the short term. Demand from German pharmacies is so high that AMP will be adding pharmaceutical distributors across Germany that focuses solely on medical cannabis in the upcoming weeks. Our goal is to become a major importer to Germany by the end of 2021"

NATIONS Cannabis, an emerging Indigenous cannabis cultivation company and the Association of Canadian Cannabis Retailers (ACCRES) share a common vision for a regulated industry that ensures a safe supply and safe access to high quality products – and have formalized their alliance with the signing of a memorandum of understanding.

The MOU is the perfect marriage whereby NATIONS will provide a farm-to-store, steady supply of cannabis products for the 26 members of the Association, representing 65 retail stores. It also presents ACCRES with an opportunity to incorporate a truly Indigenous brand into its fold with an ability to cultivate new strains where market demands change. The projected value of the agreement is $28 million in the first year, and $96 million by year three.

“The partnership is pivotal in the evolution of NATIONS”, says the company’s co-founder and Executive Chairman, Wes Sam. “We are unaware of any such agreement involving an Indigenous production company in this province, and ACCRES has identified our company as the first it has chosen to collaborate with in this manner.”

From the perspective of ACCRES, the deal is a win-win. “We believe NATIONS will become the premier and earliest Indigenous cannabis producer in BC, “said Association Interim President Mathew Greenwood. “They have a product that will allow our retailers to differentiate themselves from others in the marketplace. Furthermore, partnering with a company that gives an authentic voice to Indigenous Peoples is an important aspect of this collaboration and will be exciting for consumers.”

As a late stage applicant in the federal licensing approval process, NATIONS’ momentum was halted this spring amidst the COVID-19 pandemic and construction of its primary cultivation facility was paused. Once work resumes, the process of seeking and securing a federal cultivation and processing license will also continue.

“As investors in the NATIONS’ project, we believe that the Agreement with ACCRES represents real Indigenous economic reconciliation and participation in the Cannabis industry,” said Chief Dan George, of the Burns Lake Band (Ts’il Kaz Koh First Nation), adding, “We are excited to be part of this unique journey with NATIONS and their partners.”

Upon licensing approval by Health Canada, NATIONS hopes to actively begin the process of facilitating a direct market arrangement with ACCRES and its respective retailers. Licensing approval will also open the door to a potential producer supply agreement through BC’s Liquor Distribution Branch.

For more information about the Association of Canadian Cannabis Retailers, please visit: https://accres.ca/

For more information about NATIONS, please visit: https://www.nationscannabis.ca

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

Hear Investor ideas cannabis potcast on iTunes

Hear the investor ideas potcast on Spotify

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

about Investorideas.com

About Investorideas.com - News that Inspires Big Investing Ideas